Entries by connective

Abcam moves to new purpose-built global headquarters

Cambridge, UK – 27 February 2019 : Abcam, a global innovator in life science reagents and tools, is pleased to announce its move to new state-of-the-art global headquarters, Discovery Drive, on the Cambridge Biomedical Campus (CBC), UK, a leading hub of healthcare, science and medical research. Alan Hirzel, CEO, Abcam, commented: “Abcam has been working […]

Dr Michael Weiner wins CiteAb’s 2019 Lifetime achievement award

We are pleased to announce that Dr Michael Weiner, Abcam’s Vice President of Molecular Sciences, is the winner of CiteAb’s 2019 Lifetime achievement award. The award recognizes individuals who have made a significant contribution to the research reagent industry over a sustained period of time. Dr Andrew Chalmers, founder of CiteAb, said: “Dr Weiner has […]

Abcam expands custom services capabilities with the acquisition of Calico Biolabs

London and Cambridge, UK, 28 January 2019: Abcam plc, a global innovator in life science reagents and tools, is pleased to announce its acquisition of Calico Biolabs, a developer of custom high-quality recombinant rabbit monoclonal antibodies for diagnostics and pharmaceutical company partners. Joyce Young, Vice President of Custom Services, Abcam commented:“This acquisition strategically expands our […]

QIAGEN (Suzhou) and Abcam sign strategic MoU collaboration agreement to co-develop companion diagnostic (CDx) and in vitro diagnostic (IVD) reagents and kits for the Chinese market

Suzhou, China and Cambridge, UK, December 6: Abcam plc, a global innovator in life science reagents and tools, and QIAGEN (Suzhou) Translational Medicine Co., Ltd. (QIAGEN (Suzhou)) have signed a Memorandum of Understanding (MoU) agreement to jointly develop a pipeline of Companion Diagnostic (CDx) and In Vitro Diagnostic reagents and kits, to meet the specific […]

Abcam ‘Most Admired Company’ award

Award from Management Today celebrates the highest performing companies in British business. Abcam Plc, a leading provider of protein research tools and services, announced today it had been voted in at number 16 in Management Today’s “Britain’s Most Admired Companies (BMAC) 2018”, and 5th in the Health and Household sector. The BMAC Awards are an […]

Abcam appoints Cheri Walker, PhD, as Senior Vice President, Corporate Development

Cambridge, UK – 30 October 2018: Abcam plc, a global innovator in life science reagents and tools, announced today that it has appointed Cheri Walker, PhD, to the role of Senior Vice President, Corporate Development. Cheri is an accomplished industry professional with over 20 years’ experience in the life sciences tools and diagnostics sector. She […]

New PBS-only antibodies enable more flexible research

Cambridge, UK – 9 October 2018: Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments. Typically, antibodies are stored in a buffer composed of bovine serum albumin (BSA), glycerol and sodium azide to ensure stability. However, these components can inhibit […]

Abcam Merck collaboration produces new PD-L1 antibody for immuno-oncology research

Clone 73-10 now available to the global research community Cambridge, UK, 2 July, 2018: Abcam, a global innovator in life science reagents and tools today announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany. Developed by Abcam for use by Merck as an […]